November 5, 2026
Evommune signs $1.1bn licence deal with Hinova for EVO570
Evommune has secured exclusive rights outside Greater China to develop, manufacture and commercialise EVO570, an autoimmune therapy, from Hinova Pharmaceuticals in a licence deal worth up to around $1.1bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







